Clinical Trials on Limited Cutaneous Systemic Sclerosis in Russian Federation

Total 158 results

Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Biocad

Completed

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Recruiting

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis (MIRANTIBUS)

Multiple Sclerosis

Russian Federation
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
St. Petersburg State Pavlov Medical University

Terminated

Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
St. Petersburg State Pavlov Medical University

Recruiting

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Active, not recruiting

Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Bayer

Completed

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Eli Lilly and Company
BioMS Technology Corp.

Completed

A Study for Patients With Relapsing Remitting Multiple Sclerosis (MINDSET01)

Relapsing Remitting Multiple Sclerosis

Serbia, Bulgaria, Poland, Russian Federation, Slovakia, Ukraine
Hoffmann-La Roche

Withdrawn

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis (LEGATO)

Multiple Sclerosis

Russian Federation
Russian Academy of Medical Sciences

Unknown

Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity (ANTMS)

Spasticity, Multiple Sclerosis, Stroke, Trauma

Russian Federation
Alisa Apreleva
ALS Centre Moscow

Unknown

Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS

ALS (Amyotrophic Lateral Sclerosis) | Dysphagia | Aspiration Pneumonia | Dyspnea | Breathlessness | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Hypernasality | Dysarthria, Flaccid | Dysarthria, Spastic | Dysarthria, Mixed

Russian Federation, United Kingdom
Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Belgium, Bulgaria, Canada, Croatia, Czech Republic, Finland, Germany, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
Celgene
Celgene Corporation

Completed

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Cutaneous T-cell Lymphoma

United States, France, Germany, Poland, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Russian Federation, Ukraine, Czech Republic
GlaxoSmithKline

Completed

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Belgium, Germany, Russian Federation, Spain, Poland
Novartis Pharmaceuticals

Completed

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Relapsing-remitting Multiple Sclerosis | RRMS

Russian Federation, Ukraine, Czech Republic
Apitope Technology (Bristol) Ltd.
Aptiv Solutions; ClinStar, LLC

Completed

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

United Kingdom, Russian Federation
Nuron Biotech Inc.

Unknown

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing Remitting Multiple Sclerosis

Poland, Spain, Belarus, Bulgaria, Serbia, Ukraine, Russian Federation, Hungary, Italy, Croatia, Georgia, Lebanon
GeNeuro SA
Worldwide Clinical Trials; Institut de Recherches Internationales Servier; Les...

Completed

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (CHANGE-MS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Ukraine, Germany, Spain, Bulgaria, Serbia, Russian Federation, Hungary, Italy, Croatia, Czechia, Estonia
GeNeuro SA
Worldwide Clinical Trials; Institut de Recherches Internationales Servier; Les...

Terminated

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (ANGEL-MS)

Multiple Sclerosis, Relapsing-Remitting

Estonia, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Poland, Russian Federation, Serbia, Spain, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Relapsing Multiple Sclerosis

Japan, Russian Federation
Genzyme, a Sanofi Company

Terminated

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

Relapsing-remitting Multiple Sclerosis

Russian Federation, United States, Canada, Poland
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Croatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
Sanofi

Completed

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (TERIVA)

Multiple Sclerosis

Germany, Ukraine, Canada, Austria, Russian Federation
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Belgium, Spain, Russian Federation, France, Italy, Poland, Sweden, Turkey, Czech Republic, Japan
AB Science

Recruiting

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

Progressive Multiple Sclerosis

Spain, Sweden, France, Greece, Italy, Poland, Russian Federation, Ukraine
Genzyme, a Sanofi Company

Terminated

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (EMPIRE)

Relapsing-remitting Multiple Sclerosis

Sweden, Poland, Russian Federation, United States, Canada
Boston Scientific Corporation

Terminated

A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing Remitting Multiple Sclerosis

Spain, Germany, Belgium, Poland, France, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Spain, Czechia, Bulgaria, Serbia, Russian Federation, Ukraine, Poland, Slovakia
Genzyme, a Sanofi Company

Active, not recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

Multiple Sclerosis

Portugal, Turkey, Italy, Austria, Belgium, France, Netherlands, Poland, Russian Federation, United Kingdom
EMD Serono

Completed

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) (REPLAY)

Multiple Sclerosis

Italy, Russian Federation, United States, Argentina, Venezuela, Canada, Tunisia, France
Teva Pharmaceutical Industries, Ltd.

Terminated

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Relapsing Remitting Multiple Sclerosis

Czechia, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, United Kingdom
Sanofi

Completed

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (CLEan)

Cutaneous Lupus Erythematosus

Chile, Italy, Czechia, Mexico, Spain, Ukraine, United States, Argentina, Australia, Canada, Hungary, India, Poland, Russian Federation, United Kingdom
Avigen

Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis

Muscle Spasticity

Czech Republic, Ukraine, Germany, Russian Federation, Serbia
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)

Relapsing Multiple Scelrosis

United States, Austria, Belgium, Croatia, Germany, Taiwan, Canada, Czechia, Spain, Argentina, Australia, Peru, South Africa, United Kingdom, Bulgaria, Latvia, Lithuania, Russian Federation, India, Portugal, Italy, Turkey, Finland, France and more
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Sanofi

Active, not recruiting

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Canada, Czechia, Estonia, France, Netherlands, Russian Federation, Spain, Ukraine
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
Prof. Laszlo Czirjak
Charite University, Berlin, Germany; University of Zurich; University College... and other collaborators

Unknown

Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis

Arthritis | Systemic Sclerosis

Germany, France, Hungary, Italy, Switzerland, United Kingdom, Belgium, Croatia, Egypt, Romania, Russian Federation, Serbia, Spain, Turkey
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Novartis Pharmaceuticals

Completed

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

Hungary, Turkey, Spain, Germany, Canada, Switzerland, United States, Norway, Russian Federation, Italy, Finland, Poland
Celgene

Completed

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (RADIANCE)

Relapsing Multiple Sclerosis

Serbia, United States, Poland, Spain, Belgium, Bulgaria, Georgia, Greece, Romania, Russian Federation, Ukraine, Hungary, Italy
Sanofi

Active, not recruiting

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Multiple Sclerosis

Bulgaria, Canada, Turkey, Spain, United States, Czechia, France, Germany, Russian Federation, Ukraine
Sanofi

Completed

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

France, United States, Canada, Czechia, Estonia, Netherlands, Russian Federation, Slovakia, Spain, Ukraine

Clinical Trials on Limited Cutaneous Systemic Sclerosis in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations